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Abstract: Herein, we evaluated in vitro the anti-leishmanial activity of betulin derivatives in Venezue-
lan isolates of Leishmania amazonensis, isolated from patients with therapeutic failure. Methods: We
analyzed promastigote in vitro susceptibility as well as the cytotoxicity and selectivity of the evalu-
ated compounds. Additionally, the activity of selected compounds was determined in intracellular
amastigotes. Finally, to gain hints on their potential mechanism of action, the effect of the most
promising compounds on plasma and mitochondrial membrane potential, and nitric oxide and
superoxide production by infected macrophages was determined. Results: From the tested 28 com-
pounds, those numbered 18 and 22 were chosen for additional studies. Both 18 and 22 were active
(GI50 ≤ 2 µM, cytotoxic CC50 > 45 µM, SI > 20) for the reference strain LTB0016 and for patient iso-
lates. The results suggest that 18 significantly depolarized the plasma membrane potential (p < 0.05)
and the mitochondrial membrane potential (p < 0.05) when compared to untreated cells. Although
neither 18 nor 22 induced nitric oxide production in infected macrophages, 18 induced superoxide
production in infected macrophages. Conclusion: Our results suggest that due to their efficacy and
selectivity against intracellular parasites and the potential mechanisms underlying their leishmani-
cidal effect, the compounds 18 and 22 could be used as tools for designing new chemotherapies
against leishmaniasis.
Keywords: Leishmania; betulin derivatives; plasma membrane potential; mitochondrial membrane
potential; therapeutic failure; drug resistance
1. Introduction
Leishmaniasis is endemic in 98 countries, in which 14 million people remain infected
and more than 350 million are at risk [1,2]. Approximately 1.3 million people contract the
disease annually; 300,000 cases correspond to visceral leishmaniasis (VL) and 1,000,000 to
tegumentary leishmaniasis (TL). The estimated number of deaths from VL ranges between
20,000 and 50,000 each year [3]. However, these numbers reflect the tip of the iceberg, since
only 40 countries where the disease is endemic regularly report their health statistics to the
World Health Organization (WHO) [4].
In Venezuela, VL has a low incidence (0.03 to 0.24 per 100,000 inhabitants) [5], although
a notable under-registration of cases remains [6]. The main focus of VL is located at the
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Nueva Esparta State [5], a geographical area in which the whole life cycle of Leishmania (L.)
infantum has been described, including the dog as the main reservoir, as well as Lutzomyia
longipalpis as the insect vector [7]. TL is officially recognized as a public health problem [5,8].
A total of 66,550 cases in its various clinical forms, with an annual incidence rate that varied
between 5.3 per 100,000 inhabitants (2014) and 12 per 100,000 inhabitants (1992), have been
reported during the period 1990–2018. TL represents 99% of the cases of leishmaniasis
reported each year, of which 98% correspond to localized cutaneous leishmaniasis (LCL), 1%
mucocutaneous leishmaniasis (MCL), and 0.2% diffuse cutaneous leishmaniasis (DCL) [9].
After malaria, leishmaniasis is the protozoan parasitic disease with the highest preva-
lence worldwide (14 million people infected). It is the second in number of disability-
adjusted life years or healthy years of life lost (1.7 million), the second with the highest
mortality rate (up to 50,000 deaths per year), and the third cause of morbidity due to
communicable diseases (1,300,000 new cases per year), after malaria and tuberculosis [1–4].
There are no pharmacological treatments sufficiently effective, safe, and affordable to
combat diseases caused by kinetoplastid parasites, including Leishmania [2,10]. Progress in
the biology, epidemiology, and immunology of leishmaniasis and the characterization of the
parasite genome and proteome form the framework to design leishmaniasis chemotherapy
of the future. Approaches to the development of chemotherapeutic strategies against the
disease include optimization of the available therapy, use of active compounds against
other diseases, pharmacological target-oriented design, and evaluation of natural products
and their derivatives.
Prospects for developing an effective leishmaniasis vaccine are not immediate and
disease control is based primarily on chemotherapeutic treatment, although the arsenal
of available drugs is reduced and with significant associated toxicity; vector control is
problematic generating environmental risk; comorbidity with HIV is increasing; and finally,
almost all endemic regions exhibit a growing incidence of therapeutic failure [11–14].
Consequently, the design of more effective and safer therapeutic alternatives has become
an extraordinary and urgent need [15–17]. Meanwhile, there is a delay in the development
of new drugs, mainly due to the lack of economic stimuli that this disease represents for
the pharmaceutical companies. For example, in the 2000s, the global investment in new
antiparasitic drugs was only about 0.1% of the global asset in research [18]. Currently,
with the exception of miltefosine (MLF), the same anti-leishmanial drugs of the early last
century are still used.
Experimental development of new anti-leishmanial agents either starts from a val-
idated target or they are searched by phenotypic screening [19]. The first approach has
proved to be unsuccessful, because a powerful inhibitory agent found against an enzyme
or another particular target usually fails to have activity in the entire microorganism [20].
The second alternative involves all possible therapeutic targets and simultaneously allows
evaluation of compound activity in the cellular environment, in a much more real condition.
Thus, phenotypic screening that includes in vitro susceptibility tests and the macrophage-
amastigote model stands out as the cornerstone of studies prior to the development of
new chemotherapeutics against this disease [21]. For example, trifluoromethyl-substituted
quinolones and their analogues, as well as metronidazole derivatives have emerged as an
interesting platform to design agents against L. (L.) mexicana and L. (V.) braziliensis [22,23].
According to the WHO, plants are the largest source of medicines for humans [24]. In
fact, natural products and their derivatives are the source of 30% of the world pharmaceuti-
cal market [25]. In this scenario, extracts or compounds of plant origin, including terpenes,
phenolics, and alkaloids, can be used as a valuable starting point for the search for new
anti-leishmanial agents [18]. Among terpenoids, betulin, a pentacyclic triterpene, isolated
from the bark of trees of the genus Betula (birches), stands out [26]. The leishmanicidal
potential of some betulin derivatives has already been documented in the literature [27–30].
However, for this type of compounds, their effectiveness in New World species, or in
parasites isolated from patients with therapeutic failure, is not clear, nor is their mechanism
of action well known.
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Herein, we evaluated in vitro the anti-leishmanial activity of betulin derivatives in
Venezuelan isolates of Leishmania amazonensis [L. (L.) amazonensis], isolated from patients
with therapeutic failure. Our results suggest that, due to their efficacy and selectivity
against intracellular parasites and the mechanisms underlying their leishmanicidal effect,
some of these compounds could be used as tools for designing new chemotherapies against
leishmaniasis.
2. Materials and Methods
2.1. Parasites
Three L. (L.) amazonensis isolates were used: a reference species certified by the WHO
(MHOM/BR/77/LTB0016, LTB0016) donated by Dr. Lionel Schnur, Hebrew University-
Hadassah Medical School, Jerusalem, Israel, and two isolates (MHOM/VE/1998/MR,
VE98MR; and MHOM/VE/2000/MM, VE2000MM) obtained from patient lesions identi-
fied as such at the Dermatology Department, Institute of Biomedicine (SAIB-MPPS-UCV),
Caracas, Venezuela. The patients were diagnosed DCL and suffered therapeutic failure
against meglumine antimoniate (Glucantime®, Sanofi-Aventis (Suzano, SP, Brazil). Species
identification was performed by PCR and molecular hybridization [31]. This project
(CDCH UCV PI-09-8717-2013) was approved by the Ethics Committee from the Institute of
Biomedicine (SAIB-MPPS-UCV), Caracas, Venezuela. Isolates were kept in liquid nitrogen
until use, when parasites were thawed and cultured in blood agar-glucose enriched with
human urine [32,33].
Leishmania promastigotes were grown at 26 ◦C in semisolid blood agar supplemented
with glucose-NaCl medium (glucose 1.5%, NaCl 0.85%, w/v). Promastigotes at late log
growth phase were collected by centrifugation at 125× g for 10 min at room temperature
(RT). The medium was decanted and the cells were suspended in the appropriate medium
up to the desired cell density.
2.2. Murine Macrophages
J774.1 macrophages [34], donated by Dr. Concepción Hernández, Institute of Ex-
perimental Biology-Universidad Central de Venezuela, were used. Culture monolayers
were established in complete Roswell Park Memorial Institute medium (RPMIc; 25 mM
HEPES, 2 mM L-glutamine, 5 mg L−1 phenol red, supplemented with 10% fetal calf
serum, 2 g L−1 NaHCO3, pH 7.2, 0.02 mM 2-mercaptoethanol, and 100 U mL−1 penicillin
plus 100 µg mL−1 streptomycin), at 37 ◦C and 5% CO2. Culture medium was replaced
weekly. For the experimental procedures, cells were detached from the flasks by mechanical
procedures, washed twice with phosphate-buffered saline (NaCl 136 mM, KCl 2.6 mM,
Na2HPO4·2H2O 10 mM, KH2PO4 1.7 mM; PBS, pH 7.4), and suspended at the desired
density in RPMIc.
2.3. Compounds
Twenty-eight semisynthetic betulin derivatives (20 structurally simple and 8 hetero-
cyclic derivatives, compounds 1–20 and 21–28, respectively) were tested. The compounds,
stable at RT, were dissolved in DMSO at a concentration of 10 mM and stored at −20 ◦C un-
til use. Their synthesis and properties have been described by Alcazar et al. and references
therein [28]. A summary of their chemical formulae, structures, and molecular weights is
included in Supplementary Materials I.
2.4. Promastigote In Vitro Susceptibility
The fluorometric method of Alamar Blue® (resazurin) was used [35]. Promastig-
otes grown in biphasic agar-blood medium, at the exponential phase of growth, were
seeded in flat-bottom 96-well culture plates, at a cell density of 1 × 106 parasites mL−1
(200,000 parasites/well), in 180 µL of RPMIc without phenol red. Subsequently, either a
sole concentration (50 µM), or increasing concentrations of compounds or drugs were
applied, according to each treatment group, in volumes of 2 µL. Plates were kept at 26 ◦C,
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in a humid chamber, for 72 h. Resazurin was then added (20 µL of 10% v/v), to reach
a final concentration of 250 µM and plates were incubated for an additional 4 h. Live
parasites are metabolically active and capable of reducing non-fluorescent resazurin (blue)
to fluorescent resorufin (red). Fluorescence intensity is directly proportional to the number
of viable cells. The fluorometric reading was carried out using the appropriate wavelengths
(ex: 540 nm/em: 580 nm) in a spectrofluorometer Victor2 Wallac (Perkin Elmer, Turku,
Finland). At least two independent experiments were performed in duplicate. The effect
of trivalent antimonial [SbIII, potassium antimonyl tartrate trihydrate, Sigma-Aldrich,
(St. Louis, MO, USA)] was included as positive control of the assay. Based on growth
inhibition caused by the tested compounds, the percentage of growth inhibition compared
to untreated cells was used to calculate the GI50 as the concentration that causes 50%
inhibition of cell proliferation [36].
2.5. Cytotoxicity and Selectivity
Cytotoxicity of “active compounds” was evaluated by the fluorometric method of
Alamar Blue® [37]. In flat-bottom 96-well culture plates, J774.1 macrophages were seeded
at a cell density of 5 × 104 mL−1 (10,000 macrophages/well) in 200 µL of RPMIc. After
24 h at 37 ◦C, 5% CO2, medium was replaced by 180 µL of RPMIc, without phenol red, and
increasing concentrations of test compounds in 2-µL volumes. Plates were kept at 37 ◦C,
5% CO2 for 72 h; then resazurin was added (20 µL, 10% v/v) to a final concentration of
250 µM and plates were incubated for additional 4 h. Fluorometric readings were carried
out using the appropriate wavelengths (ex: 540 nm/em: 580 nm) in a spectrofluorometer
Victor2 Wallac (Perkin Elmer, Turku, Finland). At least two independent experiments
were performed in duplicate. Based on the inhibition of cell growth caused by the tested
compounds, the percentage of growth inhibition compared to untreated cells was calculated.
With these percentages, the concentration that causes cytotoxicity in 50% of macrophages
(CC50) of macrophages was calculated. Selectivity indices (SI) were calculated, dividing
the macrophage CC50 by the parasites GI50 (SI = CC50/GI50) [38].
2.6. Macrophage-Amastigote Model
We used a previously described methodology [39], with some modifications.
Macrophage monolayers, grown in RMPIc medium, for 3 days, were detached from the
bottom of the culture chamber, by physical treatment (low temperature and light strokes).
Obtained macrophages were seeded in flat-bottom 96-well culture plates, at a density of
2 × 105 cells mL−1 (40,000 macrophages/well), in a final volume of 200 µL. Plates were
incubated for 2 h, and the supernatant was discarded to remove non-adhered macrophages.
Medium was replaced with stationary-phase promastigotes suspended in 200 µL of RPMIc
(2 × 106 parasites mL−1, 400,000 parasites/well), at a macrophage: parasite ratio 1:10 [40].
The plates were incubated for 4 h. Afterwards the medium was replaced with fresh RPMIc
and increasing concentrations of compounds or drugs tested were applied, in volumes of
2 µL, according to the different treatment groups. Plates were kept for 72 h, at 37 ◦C and
5% CO2. The medium was discarded and the wells were washed twice with PBS. Next, a
Giemsa staining was performed in situ. It consisted of adding 200 µL of methanol/well,
incubating for 5 min, discarding the fixative, and letting it dry at room temperature. Later,
the Giemsa solution (10% in PBS w/v, 200 µL/well) was added, incubated for 10 min, and
washed with PBS, allowing it to dry. Finally, the bottom of the plates was detached by
percussion and the circular bottoms (wells) were fixed to slides with Permount synthetic
resin, for later evaluation (Alcazar W., manuscript in preparation). Cell counting was
performed with a 100× immersion objective. A minimum of 200 random macrophages
were examined. The percentage of infected macrophages (% infection) and the average
number of amastigotes present in infected macrophages (amastigotes) were determined. From
these data, the infection index (inf-I) was calculated: inf-I = % infection × amastigotes. The
infection rate represents the number of intracellular amastigotes per 100 macrophages
evaluated [40,41]. Additionally, the GI50 for the decrease in the infection rate was calculated.
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At least three independent experiments were performed. The effect of amphotericin-B
(AmB) [Sigma-Aldrich, (St. Louis, MO, USA)] was included as positive control of the assay.
2.7. Plasma Membrane Potential (∆Ψp)
To evaluate the plasma membrane potential (∆Ψp), the fluorescent compound, bisox-
onol, bis[1,3-diethylthiobarbituric acid] trimethine oxonol, was used, as well as a method [41]
optimized by Padrón-Nieves et al. [42–44]. Initially, calibration curves for each strain, using
increasing concentrations of KCl (0.5 to 75 mM), were performed in the late log growth
phase Leishmania promastigotes in the presence of the potassium ionophore valinomycin.
By this procedure, fluorescence values could be transformed into millivolts (mV), applying
the Nernst equation, ∆Ψp = −59.4 log(120/[KCl]). In 96-well plates, 200-µL aliquots of
parasitic suspension were seeded at a cell density of 1 × 106 parasites mL−1, dissolved
in a solution free of monovalent cations, N-methyl-D-glucamine hydrochloride (140 mM
NMGHCl; 0.8 mM MgCl2; 1 mM CaCl2; 10 mM HEPES; 11 mM glucose, pH 7.2). After
incubation at RT and in darkness, for 10 min, in the presence of 1 µM of valinomycin,
100 nM bisoxonol was added, and then, increasing concentrations of KCl. After 10 min of
incubation in the dark, fluorescence was measured in a Victor2 Wallac spectrofluorome-
ter (Perkin Elmer, Turku, Finland), using the appropriate wavelengths (ex: 540 nm/em:
580 nm). This method allowed us also to measure the resting ∆Ψp. Once the corresponding
calibration curve for each strain was obtained, the effect of compounds on the ∆Ψp was
evaluated. A similar procedure was followed. Briefly, in 96-well plates, 200-µL aliquots
of parasitic suspension were seeded at a cell density of 1 × 106 parasites mL−1, dissolved
in HEPES solution (HEPESs: 20 mM HEPES, 132 mM NaCl, 3.5 mM KCl, 1 mM CaCl2,
0.5 mM MgCl2, pH 7.2) with glucose (5 mM, HEPES-G). After incubation at RT and in
darkness, for 15 min, in the presence of test compounds and controls (depolarizers: 1 µM
valinomycin, 300 µM cytochalasin B; hyperpolarizers: 500 µM sodium 4,4′-diisothiocyano-
2,2′-stilbenedisulfonate, DIDS), 100 nM bisoxonol was added. After 10 min of incubation in
the dark, fluorescence was measured, using the appropriate wavelengths (ex: 540 nm/em:
580 nm). At least two independent experiments were performed in duplicate. The treat-
ments were applied in volumes of 2 µL. Valinomycin, a selective ionophore for potassium,
and cytochalasin-B, an inhibitor of glucose transport, were used as depolarizing control
compounds. DIDS, a voltage-dependent chloride channel inhibitor, was used as a hyper-
polarizing control compound. To transform the fluorescence values in millivolts (mV),
calibration curves were prepared using increasing concentrations of KCl (0.5, 1.15, 2.5, 5,
10, 20, 40, and 75 mM). This was done for the reference strain LTB0016, as well as for the
patient isolates. Finally, to calculate the plasma membrane potential, the Nernst equation
was used [∆Ψp = −59.4 log(120/[KCl])] [42–44].
2.8. Mitochondrial Membrane Potential (∆Ψm)
To evaluate the mitochondrial membrane potential (∆Ψm), the fluorescent compound
JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide) was used,
according to a modification of a previously described method [45]. Exponential phase
promastigotes were suspended at 26 ◦C, in RPMIc without phenol red, in a volume of
1 mL, at a cell density of 1 × 107 parasites mL−1. The parasites were left to grow for
48 h, in the presence and absence of the test compounds. Then, after centrifuging (500× g
for 10 min) and washing the parasites twice with PBS, they were resuspended in 200
µL of HEPES-G, and placed in 96-well plates. In the depolarizing control wells, 1 µM
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) and 20 µM oligomycin
were added. The JC-1 probe was then added, at a final concentration of 15 µM. Then, the
plates were incubated for 30 min, at RT in the dark. Finally, fluorescence was measured
in a Victor2 Wallac spectrofluorometer (Perkin Elmer, Turku, Finland) at the appropriate
wavelengths (ex: 485 nm/em: 535 and 580 nm). As the mitochondrial membrane is
polarized, JC-1 produces intra-mitochondrial aggregates “J-aggregates” that emit a red
fluorescence (λ 590 nm). Mitochondrial membrane depolarization induces JC-1 monomeric
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conformation in the cytoplasm, then the fluorescence turns green (λ 530 nm). The red/green
ratio of fluorescence then is an indirect measurement of the mitochondrial membrane
potential. A more depolarized mitochondria means a lower ratio of red/green fluorescence.
Relative fluorescence (RF) was calculated, where RF = 580 nm fluorescence/535 nm
fluorescence (red/green). A decrease in the value of RF would indicate the collapse of
the mitochondrial membrane potential. At least two independent experiments were per-
formed in duplicate. Compounds used as depolarizing controls were: FCCP, an oxidative
phosphorylation inhibitor and ionophore, which acts by decoupling the respiratory chain,
interrupting the synthesis of ATP by transporting hydrogen ions through the mitochondrial
membrane before they can be used as a source of energy; and oligomycin, an antibiotic
that inhibits mitochondrial ATPase by binding to the F0 subunit and interfering with the
transport of H+, thus inhibiting the synthesis of ATP [43].
2.9. Nitric Oxide (NO) Production
Following a previously described procedure [46,47], infected and uninfected macrophage
cultures were treated with test compounds to analyze their effect in Leishmania host cell ni-
tric oxide (NO) production. J774.1 macrophages, at the third day of growth, were collected
and seeded in flat-bottom 96-well culture plates, at a density of 1 × 106 cells mL−1 (2 × 105
macrophages/well), in 200 µL of RPMIc. The plates were incubated for 2 h; once the super-
natant was discarded, the medium was replaced with 200 µL of RPMIc mixed with infectious
promastigotes in the stationary phase of growth (1× 107 parasites/mL, 2× 106 parasites/well),
so that the ratio macrophage: parasites was 1:10 [41]. The plates were then incubated for 4 h, the
medium was replaced with fresh RPMIc and the test compounds were applied, according to the
different treatment groups. The plates were kept in incubation for 48 h, at 37 ◦C and 5% CO2.
From the culture supernatants, 50-µL aliquots were recovered and transferred to a
new 96-well plate to perform the Griess reaction [48], 50 µL of Solution 1 [1% sulfanilamide
dissolved in 2.5% phosphoric acid] was added, incubated for 5 min at RT and in the dark.
Subsequently, 50 µL of Solution 2 [0.1% N-(1-naphthyl) ethylenediamine dihydrochloride
dissolved in distilled water] was added, stirred for an additional 5 min, at RT and in the
dark. Finally, the colorimetric reading was performed at 550 nm. Three independent experi-
ments were performed in duplicate. The Griess reaction quantifies NO, using nitrite (NO2−)
as the most stable species. NO2− concentrations in culture medium reflect indirectly the
levels of NO produced by macrophages. Levels of NO2− (expressed as µM of NO2−) were
calculated from a calibration curve constructed with increasing concentrations of sodium
nitrite (NaNO2). MLF (5 µM) and AmB (0.1 µM), known to induce NO production in
macrophages, were included as controls.
2.10. Superoxide (O2−) Production
The intracellular oxidative burst was evaluated by the production of the superoxide
anion O2−, using the method of reduction of ferricytochrome c, previously described [46].
Macrophages from preceding experiments were used after removing the supernatant; the
cells pretreated with compounds or AmB as positive control of the experiment were resus-
pended in 100 µL of Hanks saline (HBSS: 137 mM NaCl, 5.4 mM KCl, 1 mM MgSO4·7H2O,
1.3 mM CaCl2·H2O, 0.3 mM Na2HPO4, 0.44 mM KH2PO4, 4.2 mM NaHCO3, 5 mM glucose,
pH 7.2) and incubated for 1 h in the presence of 2 mg mL−1 (160 µM) of cytochrome c
type III, at 37 ◦C and 5% CO2. The supernatant was saved to measure the change in optical
density at 550 nm. Three independent experiments were performed in duplicate. The su-
peroxide anion concentration was calculated using the reduced molar extinction coefficient
of cytochrome c, 21 mM−1 cm−1. Therefore, [O2−] = (∆OD/6.3) × 100, where ∆OD is the
variation of the optical density (reading-blank), and the result obtained corresponds to the
concentration of superoxide anion expressed in nanomoles of O2− released/2 × 105 cells.
MLF (5 µM) and amphotericin-B (AmB, 0.1 µM), known to induce NO production in
macrophages, were included as controls.
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2.11. Statistics
GraphPad Prism 8 software (2018, San Diego, CA, USA) was used. The Kolmogorov–
Smirnov normality test and the Barlett test for homogeneity of variances, with a 95%
confidence, were used to test the null hypothesis that the data were taken from a Gaussian
distribution. Since the value of p > 0.05 showed that the data did not deviate from the
normal distribution, the variance analysis and the Bonferroni multiple comparisons test
were used to compare the results between different test conditions [49]. Results were
expressed as mean ± standard error of the mean. In all tests, a value of p < 0.05 was
considered statistically significant. GI50 and CC50 values were calculated by non-linear
regression of the sigmoid response dose curve with variable slope [50]. Supplementary
Materials III includes tables of the statistical analysis performed for each of the methods
used to analyze the potential mechanism of action of compounds.
3. Results
3.1. Selection of the Tool Compounds
To select compounds that may be interesting for their potential anti-leishmanial
activity, 20 structurally simple (compounds 1–20) and 8 heterocyclic (compounds 21–28)
betulin derivatives [28,29] were evaluated by their capacity to inhibit reference strain
(LTB0016) growth at one sole concentration of 50 µM (upper limit to consider their clinical
value) [38]. For details on their chemical formula, structure, and molecular weight, please
consult Supplementary Materials I.
A total of eight compounds that reduced at least 75% of parasite growth were for-
warded to the next step of analysis as “active compounds”. These compounds were tested
at increasing concentrations to find out their GI50 against the Leishmania reference strain.
Three simple betulin derivatives (1, 17, and 18) reduced parasite growth to less than
25%, with 18 being the most active compound, reducing promastigote growth to 3.32%
compared to untreated cells. Five heterocyclic betulin derivatives (22, 24, 25, 26, 27) reduced
parasite growth to less than 25%, with 26 being the most active compound, reducing
promastigotes growth to 4.28%.
To quantify the leishmanicidal effect of the best compounds of both groups of betulin
derivatives, GI50 was determined in promastigotes of LTB0016, at increasing concentrations
from 1 to 100 µM and 72 h of incubation (see Table 1).






Promastigote (GI50) Macrophages J774.1 (CC50) SI
X(µM) IL SL X(µM) IL SL CC50/GI50
1 1 19.76 19.33 14.14 24.53 25.08 8.95 41.22 1.30
17 1 6.49 1.35 −0.03 2.74 19.26 10.10 28.41 14.23
18 1 3.32 0.90 0.24 1.55 48.09 33.17 63.01 53.63
22 2 7.98 1.98 0.99 2.98 61.13 52.91 69.35 30.82
24 2 10.26 9.05 6.95 11.15 51.06 34.78 67.34 5.64
25 2 11.70 6.46 2.63 10.30 65.93 51.76 80.10 10.20
26 2 4.28 3.85 −0.23 7.93 21.86 15.72 28.00 5.68
27 2 7.34 4.23 0.42 8.04 21.12 16.86 25.38 4.99
SbIII ND 5.51 4.92 6.08 ND ND ND ND
AmB ND 0.068 0.05 0.08 ND ND ND ND
PNT ND 0.93 0.51 1.35 ND ND ND ND
MLF ND 4.17 3.79 4.54 ND ND ND ND
LTB0016 promastigotes and J774.1 macrophages were exposed to increasing concentrations (1, 5, 10, 50, and 100 µM) of the compounds
for 72 h. Summarized data are expressed as the mean concentration (X) of three independent experiments performed in duplicate,
including 95% confidence interval (IL: inferior limit, SL: superior limit). GI50 and CC50 values were determined by lineal regression of dose
response curves with variable slope, using the GraphPad Prism 8/2018. GI50: 50% inhibitory growth concentration, CC50: 50% cytotoxic
concentration, SI: selectivity index. 1 Simple betulins, 2 heterocyclic betulins. SbIII was used as control to evaluate the susceptibility of
extracellular parasites, since it is well described that Leishmania promastigotes are not susceptible to SbV. AmB, PNT, and MLF were used as
control commercial drugs to compare the susceptibility of promastigotes.
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One-way ANOVA analysis, followed by Bonferroni test, allowed identification of sig-
nificant differences (p < 0.05) of the tested compounds vs. SbIII [GI50 = 5.51
(IL = 4.92–SL = 6.08 µM] against promastigotes. Compounds 17, 18, 22, 26, and 27 were as
effective as the reference compound to inhibit LTB0016 growth. However, a significant
difference against SbIII (p = 0.0413) was only detected for 18, being even stronger than it.
Potential cytotoxicity was evaluated in J774.1 macrophages. Due to their low cytotoxicity,
18 and 22 presented the best SI (SI > 15) and were forwarded to the next step of research.
3.2. Effect of Compounds on Intracellular Amastigotes
To confirm the anti-leishmanial effect of the compounds 18 and 22, GI50 was de-
termined for intracellular amastigotes of reference strain LTB0016 and patient isolates,
using the amastigote-macrophage model. Thus, infected macrophages were exposed to
increasing concentrations of 18 and 22 (0.1, 0.5, 1, 5, and 10 µM). The infectious index data
is included as Supplementary Materials (Supplementary Materials II). Final results are
summarized in Table 2. Compounds 18 and 22 showed GI50 < 1 µM and can be considered
safe in their toxicity against J774.1 macrophages (SI > 20), both for reference strain LTB0016
and patient isolates.
Table 2. In vitro activity of compounds against intracellular amastigotes of the reference strain LTB0016 and patient isolates
VE98MR and VE2000MM.
GI50 (µM) MØ J774.1 SI (CC50/GI50)
LTB0016 VE98MR VE2000MM CC50 1 (µM) LTB0016 VE98MR VE2000MM
18 0.20 1.76 0.72 48.09 240.45 27.32 66.79
22 0.21 0.63 1.69 61.13 291.10 97.03 36.17
AmB 0.020 0.073 0.080 >10 >500 >136 >125
LTB0016, VE98MR, and VE2000MM intracellular amastigotes and J774.1 macrophages were exposed to increasing concentrations of the
control drug AmB or experimental compounds 18 and 22 for 72 h. Data are presented as mean values of three independent experiments.
GI50 and CC50 values were determined by lineal regression of dose–response curves using GrapPad Prism 8/2018. GI50: 50% inhibitory
growth concentration, CC50: 50% cytotoxic concentration, SI: selectivity index. 1 The CC50 values for compounds 18 and 22 come from
Table 1.
3.3. In the Search of the Mechanism of Action of Betulin Derivatives
In the search of the mechanism of action of the selected compounds, their effect on
the plasma membrane potential and mitochondrial membrane potential was evaluated in
promastigotes. In non-infected and infected macrophages, the effect of selected compounds
was evaluated on nitric oxide production and on superoxide production.
3.3.1. Plasma Membrane Potential (∆Ψp) in Promastigotes
To evaluate the effect of the most promising compounds on the plasma membrane
potential (∆Ψp), promastigotes were exposed during 15 min to 18 and 22. Selected con-
centrations were their GI50 and twice GI50 (18, 1 and 2 µM; 22, 2 and 4 µM). Untreated
cells, as well as cells treated with depolarizing molecules (valinomycin, 1 µM; cytocha-
lasin B, 300 µM) and one hyperpolarizing compound (DIDS, 500 µM) were included. As
the depolarizing probe, the lipophilic anion bisoxonol [100 nM] was used.
The resting ∆Ψp of parasites was then established (LTB0016: −181.97 ± 19 mV;
VE98MR = −166.75 ± 11 mV and VE2000MM = −158.30 ± 8 mV). The isolates presented
more depolarized resting membrane potentials than the reference strain (see Supplementary
Materials III for statistics).
Figure 1 demonstrates that only 18 was able to significantly depolarize the ∆Ψp in
all evaluated strains when compared to untreated controls (p < 0.05). The effect was
similar to that depicted by valinomycin and concentration dependent, except in the case of
VE2000MM. This strain was not sensitive to valinomycin.
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Figure 1. Effect of betulin derivatives on plasma membr ne potential (∆Ψp) in L. ( .) amazonensis
reference strain LTB0016 and isolates VE98MR and VE2000MM promastigotes isolated from patients,
at two increasing concentrations (a and b): 18 (1 and 2 µM), 22 (2 and 4 µM), incubated for 15 min.
Each bar or point represents the average (n = 3 to 6 independent experiments) with its standard error
(SEM). * p < 0.05; ** p < 0.005; *** p < 0.0005 compared to control without treatment. Control: without
treatment; VAL: valinomycin, 1 µM; CytB: cytochalasin B, 300 µM; DIDS: sodium 4,4’-diisothiocyano-
2,2’-stilbenedisulfonate, 500 µM.
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3.3.2. Mitochondrial Membrane Potential (∆Ψm) in Promastigotes
To evaluate if the effect of the betulin derivatives on parasites was related to their
action on mitochondria, or related to programmed cell death, their effect on the mito-
chondrial membrane potential (∆Ψm) was evaluated. Promastigotes were exposed to two
concentrations of the compounds, equivalent to their GI50 and twice GI50 (as before, 18: 1
and 2 µM; 22: 2 and 4 µM), during 48 h. As controls, untreated cells, as well as cells treated
with depolarizing compounds (FCCP 1 µM and oligomycin 20 µM) were included. As the
label for ∆Ψm, the lipophilic cationic probe JC-1 was used.
Figure 2 demonstrates how 18 depolarizes ∆Ψm in a concentration-dependent way
when compared to untreated cells (p < 0.05) in all studied cells. The effect of 18 at its higher
concentration (2 µM) in LTB0016 and VE98MR was comparable to that of oligomycin
20 µM, a compound that quickly inhibits the mitochondrial ATPase and ATP synthesis.
22 also inhibited ∆Ψm, and a significant difference (p = 0.025) was only present at the
highest concentration used (4 µM) and for LTB0016 (see Supplementary Materials III for
statistical details).
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Figure 2. Effect of betulin derivatives on mitochondrial membrane potential (∆Ψm) in L. (L.) amazo-
nensis reference strain LTB0016 and isolates VE98MR and VE2000MM promastigotes isolated from
patients, at two increasing concentrations (a and b): 18 (1 and 2 µM), 22 (2 and 4 µM), incubated for
48 h. Each bar represents the average (n = 3 independent experiments in duplicate) with its respective
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1 µM; OLIG: oligomycin, 20 µM.
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3.3.3. Nitric Oxide Production (NO) in Macrophages
To evaluate if the anti-leishmanial activity of compounds 18 and 22 is related to mod-
ulating effects on the microbicidal activity of macrophages, non-infected and infected
cultured macrophages were exposed to two concentrations of the compounds, promastig-
ote GI50 and twice GI50 (18: 1 and 2 µM; 22: 2 and 4 µM). The NO production was indirectly
determined through the evaluation of nitrite (NO2−) levels by the Griess reaction. Com-
pounds 18 and 22 were not capable of inducing NO production in any of the strains tested
(Figure 3). Supplementary Materials III details the associated statistics.
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4. Discussion
Pentacyclic triterpenes like betulin and lup-20(29)-ene-3ß,28-diol, are isolated from
birch outer bark (Betula sp . Betulaceae) ith a yield around 30% of dry mat er [51].
Derivatives from t e betulin compound can be chemically modified at
t e hydroxyl group C-3, the double bond -20, pri ary hydroxyl C-28. Betulin
derivatives with anti-leishmanial properties have be n described previously [27–30].
Although plant extracts and compounds against L. (L.) amazonensi [52–5 ] have be n
thoroughly evaluated, the betulin derivatives herein described have be n tested against
New World Leishmania spp. t against patient isolates with therapeutic failure. In
the present work, two L. (L.) amazonensis Venez ela , i fro patients with
therapeutic failure against SbV, were us d to characterize the activity of betulin derivatives.
Here, 28 semisynthetic betulin derivatives selected according to Alakurtti et al. [29,55]
were tested at 50 µM. Eight compou ds showed an anti-leishmanial effect (1, 17, 18, 22,
24, 25, 26, and 27), inhibiting L. (L.) amazonensis growth by at least 75%. Previously, we
demonstrated that derivatives 14, 17, 18, 25, 26, and 27 were active at less than 10 µM in
L. (L.) braziliensis, reference strain MHOM/BR/LTB300, and that 18, 26, and 27 inhibited
parasite migration at nano and picomolar concentrations, suggesting a chemotactic effect
of betulin derivatives that might be vital for host–parasite interaction [28].
The corresponding promastigote GI50 against the reference compounds (AmB, PNT,
SbIII, MLF) were defined. As pentavalent antimonials (SbV) constitute pro-drugs that
need biological reduction to their trivalent form (SbIII) to be leishmanicidal [56], we used
the latter as potassium antimonyl tartrate trihydrate instead of the pentavalent form,
meglumine antimoniate.
Promastigotes of Venezuelan isolates herein analyzed were less susceptible to SbIII
(VE98MR, GI50 = 9.08 µM; VE2000MM, GI50 = 13.60 µM) than the reference strain (LTB0016
GI50 = 5.51 µM). Additionally, VE2000MM was slightly less susceptible to MLF (GI50 = 5.13
µM) than the reference strain (LTB0016 GI50 = 4.17 µM). These results suggest that VE98MR,
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and specifically VE2000MM, might be parasites refractive to conventional treatments, thus
being suitable isolates for in vitro evaluation of new anti-leishmanial compounds.
Data not detailed in this manuscript suggest that the isolates’ susceptibility against
NaNO2 was such that GI50 was four-fold higher (VE98MR, GI50 = 3.28 µM; VE2000MM,
GI50 = 4.79 µM) than the reference strain (LTB0016, GI50 = 0.91 µM), thus suggesting that the
Leishmania isolates, obtained from patients suffering therapeutic failure against meglumine
antimoniate, can be classified as chemoresistant as has been described for antimonial-
resistant L. (L.) infantum isolated from Brazilian patients with therapeutic failure [57].
Additionally, the GI50 against K2Cr2O7 (>2.5 mM) for both isolates was significantly higher
than that obtained for the reference strain (LTB0016 GI50 = 1.06 mM); similar results have
been published for SbV-resistant L. (L.) donovani tolerant to K2Cr2O7 [58].
As compounds 18 and 22 [25,59] were classified as effective and relatively secure
(GI50 ≤ 2 µM, cytotoxic CC50 > 45 µM, SI > 20), they were furthered to explore their
mechanism of action.
In the amastigote-macrophage model, the isolates (GI50: VE98MR = 1.76 µM,
VE2000MM = 0.72 µM) were less susceptible to 18 than the reference strain LTB0016
(GI50: = 0.20 µM). Similar results were obtained for 22; the less susceptible isolate,
VE2000MM, demonstrated a GI50 of 1.69 µM, and the reference strain of 0.21 µM. VE98MR
and VE2000MM might be less susceptible due to potential cross-resistance mechanisms
between SbV and betulin derivatives as more than 3-fold doses were needed to reach
similar effects in isolates vs. the reference strain.
These concentrations did not affect macrophages’ viability (SI > 20), suggesting that
18 and 22 are worthy of being analyzed as potential candidates against parasites refractory
to conventional treatment, as has been tested against L. (L.) donovani susceptible to SbV or
selected as resistant to the same compound [60], as well as against Plasmodium falciparum
(clone W2), resistant to chloroquine [61] for which betulin derivatives like O-disuccinoyl
betulin, betulonic acid, and other betulinic acid derivatives have proved to be effective.
Our results suggest that GI50 values for 18 in L. (L.) amazonensis LTB0016 (GI50 pro-
mastigote = 0.90 µM; GI50 amastigote = 0.20 µM) were lower than those described for the
same compound in L. (L.) donovani axenic amastigotes (GI50 = 22.80 µM) [29]. Differences
may respond to species-specific internal factors, with L. (L.) donovani being intrinsically
less susceptible to 18 than L. (L.) amazonensis. Alternatively, the used parasitic stage, axenic
amastigotes vs. intracellular amastigotes, may be influencing the obtained results.
Our data suggest that the carboxyl group at position C28 is not indispensable for
betulin anti-leishmanial activity, as suggested for L. (L.) major [62]. For example, 11 (be-
tulinic acid), at 50 µM, inhibited L. (L.) amazonensis LTB0016 growth by 44%; other carboxyl
compounds, (13 and 14) did not show enough anti-leishmanial activity.
In L. (V.) braziliensis promastigotes, the most potent compound was 26 (3,28- diformyl-
betulin triazolodione) with a GI50 < 1 µM [29]. Likewise, a betulin aldehyde derivative
reduced infection up to 88% at 136 µM and 58% at 68 µM of intracellular L. (L.) amazonensis
amastigotes [63]. Herein, 26 was also within the initially selected compounds. However,
as previously mentioned, only 18 and 22 showed significant differences that made them
worthy of further analysis. These results support our data regarding the moderate activity
identified for betulinic aldehyde (12) that at 50 µM inhibited L. (L.) amazonensis growth by
67% and suggest that there might be species variances that could explain the differences
herein found when compared to previous data in L. (V.) braziliensis.
Compound 22 is a heterocyclic adduct between 3,28-di-O-acetyllupa-12,18-diene and
4-ethylurazine, while the structurally related 25 is another heterocyclic adduct between 3,28-
di-O-acetyllupa-12,18-diene and 4-methylurazine [55]. Compound 25, although cytotoxic
at all evaluated concentrations, is an effective derivative with a GI50 of 8.9 µM, in L.
(L.) donovani axenic amastigotes. On the other hand, 22, was slightly toxic for J774.1
macrophages (CC50 = 61.13 µM) with minimal GI50 against L. (L.) amazonensis intracellular
amastigotes = 0.21 µM), and very high selectivity index (SI = 291). Heterocyclic derivatives
bulkier in C3, C28, or N4 were less active.
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The anti-leishmanial activity of betulin derivatives associates in Old World Leishmania
with inhibitory effects over enzymes fundamental for parasite survival, such as topoiso-
merase IB [64] and trypanothione synthetase, TryS [65] as well as on the promoted parasite
oxidative stress that ends up in programmed cell death [66]. However, specific targets and
molecular mechanisms involved in their action still are not completely understood [67],
and for New World species are not known at all. Herein, we explored their mechanism of
action.
In organisms like protozoa, bacteria, pathogenic fungi, and tumor cells, betulin deriva-
tives’ target seems to be located at the plasma membrane [68]. Examples also exist in
Leishmania that illustrate the effect of compounds on the membrane, specifically affecting
the ∆Ψp, i.e., AmB in L. (L.) infantum [69], clomipramine and imipramine in L. (L.) donovani
and L. (L.) major [70] or peptides like cecropin-A and melittin in L. (L.) donovani [71], or
lupeol, an anti-leishmanial triterpene from Sterculia villosa for L. (L.) infantum [72], and L.
(L.) donovani [73]. In this line of evidence, we report that betulin derivative 18, induced,
in a very short time (15 min), the collapse of the plasma membrane potential (∆Ψp) in a
concentration-dependent way. The effect was comparable to that imposed by valinomycin
(1 µM) and cytochalasin B (300 µM).
On the other hand, betulin 1 and betulin derivatives induce programmed cell death in
L. (L.) donovani promastigotes [66] and the betulin derivative O-disuccinoyl betulin induces
non-dependent caspase apoptosis [64]. The effect of 1 in L. (L.) donovani correlates with the
inhibition of TryS [65], resulting in intracellular redox homeostasis loss [66].
Besides that, medicinal plants and their secondary metabolites may have immunomod-
ulatory properties [74] [superoxide (O2−) and nitric oxide (NO) production], potentially
useful against leishmaniasis [75]. L. major amastigote elimination depends preferentially
on NO production [75] and L. (V.) braziliensis abolition seems to strictly depend on both
O2− and ROS generation [76]. Of note, in macrophages infected with L. (L.) donovani, lu-
peol induced NO production and increased the production of proinflammatory cytokines,
decreasing the production of anti-inflammatory cytokines [73].
Nitric oxide is essential for macrophage activation and is produced in Leishmania-
infected macrophages [77,78]; additionally, metacyclic L. amazonensis promastigotes pro-
duce NO and axenic amastigotes produce NO levels 10-fold higher than those produced
by metacyclic promastigotes as has been described by Acuña and collaborators (2017) [79]
and references within. However, similar to what we herein described in both the reference
strain and patient isolates and in L. amazonensis-infected macrophages, there is a lower
production of NO than in un-infected macrophages. L. amazonensis seems to have an
adaptive strategy to escape from host defense. This strategy seems to be produced by the
activation of the NF-κB repressor complex p50/p50, a specific host transcriptional response
that negatively regulates the expression of inducible nitric oxide synthase. This feature
seems to favor the establishment and success of L. amazonensis infection [80].
In our hands, 18 and 22 were not capable of inducing NO production for any of the
strains tested. However, compound 18 seems to influence the oxidative response of J774.1
macrophages infected with L. (L.) amazonensis LTB0016 and VE98MR, inducing an oxidative
burst and thus increasing O2− production.
Considering the structural similarity between lupeol and betulin derivatives, both
terpenoids may be addressing the same cellular target. Molecular docking analysis [73]
suggests that these compounds may be capable of attachment to the parasite surface protein
GP63, thus affecting the cells’ signaling processes that lead to macrophage activation [81].
On the other hand, an in silico analysis of a 58-member library of betulin derivatives
(including 18) identified the membrane transport protein D1 as a potential target for this
compound in L. (L.) donovani [67].
Finally, whether molecular functional events associated with the production of non-
caspase-dependent apoptosis in L. (L.) donovani [64] and produced by O-disuccinoyl be-
tulin [66] or inhibition of TryS [65]) are affected by betulin derivatives like compound 18 in
L. (L.) amazonensis has to be further analyzed.
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Altogether, our results suggest that diverse targets might be addressed by 18 in
L. (L.) amazonensis. Therefore, further experiments are needed to fully elucidate the final
mechanism of action of this compound.
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